cs / en
Logo

Current survival measures

In the modern era of treatment for chronic myeloid leukemia (CML) by tyrosine kinase inhibitors (TKIs), the prognosis has considerably improved. Even patients, who have relapsed, can achieve disease remission once or even repeatedly. However, common methods for evaluating survival of patients or cumulative incidence of responses to treatment do not enable to analyze multiple remissions. Therefore, a team of data analysts from the Institute of Biostatistics and Analyses and hematologists from CELL has developed the so-called Current Survival Measures:

  • Current cumulative incidence (CCI), which is the probability that a CML patient is alive and in any disease remission after initiating his or her TKI therapy.

  • Current leukaemia-free survival (CLFS), which is the probability that a CML patient is alive and in any disease remission after achieving the first disease remission on TKI therapy.

 

Folber F., Koriťáková E. Portál české leukemické skupiny [online]. 2016 [cit. 2019-7-18]. Dostupné z: http://www.leukemia-cell.org.

2019 CELL - the Czech leukemia study group for life | site map